Compare REAX & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REAX | ANNX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.1M | 918.2M |
| IPO Year | N/A | 2020 |
| Metric | REAX | ANNX |
|---|---|---|
| Price | $2.74 | $4.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.90 | ★ $16.50 |
| AVG Volume (30 Days) | 1.6M | ★ 2.2M |
| Earning Date | 03-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,813,907,000.00 | N/A |
| Revenue This Year | $57.12 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.60 | N/A |
| 52 Week Low | $2.55 | $1.29 |
| 52 Week High | $5.65 | $7.18 |
| Indicator | REAX | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 41.00 |
| Support Level | $2.55 | $5.09 |
| Resistance Level | $3.28 | $5.79 |
| Average True Range (ATR) | 0.20 | 0.40 |
| MACD | -0.07 | -0.19 |
| Stochastic Oscillator | 16.27 | 10.29 |
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.